PMID- 38516338
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240323
IS  - 2405-6308 (Electronic)
IS  - 2405-6308 (Linking)
VI  - 46
DP  - 2024 May
TI  - Ultra-hypofractionated one-week locoregional radiotherapy for patients with early 
      breast cancer: Acute toxicity results.
PG  - 100764
LID - 10.1016/j.ctro.2024.100764 [doi]
LID - 100764
AB  - PURPOSE: Moderate hypofractionated radiotherapy is the standard of care for all 
      patients with breast cancer, irrespective of stage or prior treatments. While 
      extreme hypofractionation is accepted for early-stage tumours, its application in 
      irradiating locoregional lymph nodes remains controversial. MATERIALS AND 
      METHODS: A prospective registry analysis from July 2020 to September 2023 
      included 276 patients with early-stage breast cancer treated with one-week 
      ultra-hypofractionation (UHF) at 26 Gy in 5 fractions on the whole breast 
      (58.3 %) or thoracic wall (41.7 %) and ipsilateral regional lymph nodes and 
      simultaneous integrated boost (58.3 %). Primary endpoint was assessment of acute 
      adverse events (AEs). Secondarily, onset of early-delayed toxicity was assessed. 
      A minimum 6-month follow-up was required for assessing potential 
      treatment-related early-delayed complications. Acute or late complications 
      attributable to treatment were assessed at inclusion using the Common Terminology 
      Criteria for Adverse Events (CTCAE) v5.0 criteria. RESULTS: With a median 
      follow-up of 19 months (range 1-49 months), 159 (57.6 %) patients reported AEs, 
      predominantly grade (G) 1 (n = 139, 50.4 %) and G2 (n = 20, 7.8 %). Skin acute 
      toxicity was common (G1/2: 134, G3: 14), while breast oedema occurred in 10 
      patients (G1: 9, G2: 1), and 15.9 % reported breast pain (G1: 42, G2: 2). 
      Ipsilateral arm oedema was observed in 1.8 % patients. For patients with a 
      follow-up beyond 6 months (n = 213), 23.4 % patients reported G1/G2 skin AEs, 
      8.8 % had G1/G2 breast/chest wall oedema, and 8.9 % experienced arm lymphedema. 
      There were no cases of brachial plexopathy or G3 toxicity in this group of 
      patients. CONCLUSIONS: One-week UHF adjuvant locoregional radiation is 
      well-tolerated, displaying low-toxicity profiles comparable to other studies 
      using similar irradiation schedules.
CI  - (c) 2024 The Author(s).
FAU - Ratosa, Ivica
AU  - Ratosa I
AD  - Division of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, 
      Slovenia.
AD  - Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Montero, Angel
AU  - Montero A
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
AD  - Facultad de Ciencias de la Salud, Universidad Camilo Jose Cela, Madrid, Spain.
FAU - Ciervide, Raquel
AU  - Ciervide R
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Alvarez, Beatriz
AU  - Alvarez B
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Garcia-Aranda, Mariola
AU  - Garcia-Aranda M
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Valero, Jeannette
AU  - Valero J
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Chen-Zhao, Xin
AU  - Chen-Zhao X
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Lopez, Mercedes
AU  - Lopez M
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Zucca, Daniel
AU  - Zucca D
AD  - Department of Medical Physics, HM Hospitales, Madrid, Spain.
FAU - Hernando, Ovidio
AU  - Hernando O
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Sanchez, Emilio
AU  - Sanchez E
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - de la Casa, Miguel Angel
AU  - de la Casa MA
AD  - Department of Medical Physics, HM Hospitales, Madrid, Spain.
FAU - Alonso, Rosa
AU  - Alonso R
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
FAU - Fernandez-Leton, Pedro
AU  - Fernandez-Leton P
AD  - Department of Medical Physics, HM Hospitales, Madrid, Spain.
FAU - Rubio, Carmen
AU  - Rubio C
AD  - Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20240313
PL  - Ireland
TA  - Clin Transl Radiat Oncol
JT  - Clinical and translational radiation oncology
JID - 101713416
PMC - PMC10955656
OTO - NOTNLM
OT  - Breast/chest wall radiotherapy
OT  - Regional node irradiation
OT  - Ultra-hypofractionation
COIS- None.The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/03/22 06:44
MHDA- 2024/03/22 06:45
PMCR- 2024/03/13
CRDT- 2024/03/22 04:10
PHST- 2024/01/17 00:00 [received]
PHST- 2024/02/26 00:00 [revised]
PHST- 2024/03/11 00:00 [accepted]
PHST- 2024/03/22 06:45 [medline]
PHST- 2024/03/22 06:44 [pubmed]
PHST- 2024/03/22 04:10 [entrez]
PHST- 2024/03/13 00:00 [pmc-release]
AID - S2405-6308(24)00041-7 [pii]
AID - 100764 [pii]
AID - 10.1016/j.ctro.2024.100764 [doi]
PST - epublish
SO  - Clin Transl Radiat Oncol. 2024 Mar 13;46:100764. doi: 10.1016/j.ctro.2024.100764. 
      eCollection 2024 May.